文献速递关节外科骨质疏松与代谢性骨病

围手术期继续使用生物制剂增加炎症性关节病患者假体周围感染风险

Perioperative Continuation of Biologic Medications Increases Odds of Periprosthetic Joint Infection in Patients With Inflammatory Arthropathy.
PubMed 文献 · J Arthroplasty · 2021-02-13

该研究基于美国退伍军人事务部数据库2005至2018年数据,回顾性分析炎症性关节病接受初次全关节置换术后1年内发生假体周围感染的患者,并与匹配对照比较围手术期生物制剂继续使用情况。结论提示围手术期继续使用生物制剂与假体周围感染相关,支持现行指南建议术前停用生物制剂。

要点

  • 炎症性关节病患者初次全关节置换围手术期继续使用生物制剂与假体周围感染风险升高相关。
  • 结果支持美国髋膝关节外科医师协会指南:术前停用生物制剂,手术安排在给药周期末,伤口愈合后恢复用药。

核心结论

  • 在本研究有限样本量下,围手术期继续使用生物制剂与炎症性关节病患者全关节置换术后假体周围感染存在关联。

研究设计与样本

  • 回顾性队列研究,数据来自美国退伍军人事务部企业数据仓库2005至2018年,纳入炎症性关节病使用生物制剂行初次全关节置换的患者。
  • 比较术后1年内发生假体周围感染者(n=26)与未发生感染的匹配对照(n=58)的围手术期生物制剂使用情况。

关键数值与推荐

  • 生物制剂暂停定义为术前中断用药、手术安排在给药周期结束后、伤口愈合后恢复用药。
  • 美国髋膝关节外科医师协会指南建议:全关节置换术前停用生物制剂,手术安排在给药周期末,伤口愈合后恢复用药。

临床怎么用

  • 对使用生物制剂的炎症性关节病患者行初次全关节置换前,应按照指南停用生物制剂并将手术安排在给药周期末,伤口愈合后再恢复用药。

局限性

  • 研究样本量有限(感染组26例,对照组58例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rates of prosthetic joint infection (PJI) are elevated among patients with inflammatory arthropathy (IA). The effect of continuing biologic drugs perioperatively with regard to PJI is unknown. The purpose of this study is to compare rates of perioperative biologic continuation in IA patients who did and did not develop PJI after primary total joint arthroplasty (TJA). METHODS: All cases of PJI within 1 year of primary TJA in IA patients on biologic medications were retrospectively reviewed from 2005 to 2018 in the US Veterans Affairs Corporate Data Warehouse. Matched controls who did not develop PJI after TJA were populated from the same database. Biologic suspension, defined as medication interruption prior to TJA with surgery occurring after the end of the dosing cycle and resumption after wound healing, was compared among cases and controls. RESULTS: Biologic medications were continued through surgery in 35% (9/26) of patients who developed PJI compared to 14% (8/58) of controls (P = .031; adjusted odds ratio of 3.46 [1.11-10.78]). No significant difference existed among cases (n = 26) and controls (n = 58) for age, gender, procedure, body mass index, rates of diabetes or chronic kidney disease, smoking status, or preoperative opioid use (all P > .05). CONCLUSION: With the limited sample sizes available in this study, we found an association with perioperative continuation of biologic medications and PJI. This data may provide support for current guidelines from the American Association of Hip and Knee Surgeons to withhold biologics before TJA with surgery scheduled at the end of the dosing cycle and medication resumption only after wound healing.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Carlson VR, Anderson LA, Lu CC, et al. Perioperative Continuation of Biologic Medications Increases Odds of Periprosthetic Joint Infection in Patients With Inflammatory Arthropathy. J Arthroplasty. 2021. PMID: 33653628. doi:10.1016/j.arth.2021.02.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。